<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04902885</url>
  </required_header>
  <id_info>
    <org_study_id>B02B00801-TRILA-301</org_study_id>
    <nct_id>NCT04902885</nct_id>
  </id_info>
  <brief_title>Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>G1 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, double-blind, placebo-controlled, multi-center Phase 3 study evaluating&#xD;
      efficacy, safety and pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung&#xD;
      Cancer Patients Receiving Carboplatin combined with Etoposide or Topotecan The study consists&#xD;
      of 2 parts: Part 1: safety run-in and pharmacokinetics evaluation of 12 ES-SCLC patients (6&#xD;
      each for first line and second/third line ES-SCLC patients); Part 2: randomized,&#xD;
      double-blind, placebo-controlled efficacy confirmation study of 80 ES-SCLC patients&#xD;
      (stratified by first line and second/third line ES-SCLC, ECOG PS [0-1 vs 2] and brain&#xD;
      metastases.&#xD;
&#xD;
      The study includes screening period, treatment period, safety follow-up and survival&#xD;
      follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) for part 1 study</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach peak concentration (Tmax) for part 1 study</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (T1/2) for part 1 study</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for part 1 study</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) for part 1 and part 2 study</measure>
    <time_frame>up to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs) for part 1 and part 2 study</measure>
    <time_frame>up to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs Leading to Study Drug Discontinuation for part 1 and part 2 study</measure>
    <time_frame>up to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of severe neutropenia (SN) in Cycle 1;</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of SN;</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of red blood cell (RBC) transfusion (at and after Week 5)</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of G-CSF treatment;</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Composite endpoints-important hematologic AEs (anyone of the followings):</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
    <description>All-cause hospitalization; All-cause dose reduction; Febrile neutropenia; Prolongation of Severe neutropenia (over 5 days); Infusion of red blood cell (RBC) infusion (at and after Week 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3 and Grade 4 hematological toxicity;</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of absolute neutrophil count in each cycle;</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of absolute neutrophil count, platelet count, absolute lymphocyte count (ALC) and hemoglobin over time;</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ESA treatment;</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of intravenous or oral antibiotics;</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of serious infectious adverse events;</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of serious adverse events of lung infection:</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of febrile neutropenia;</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of platelet transfusion</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate;</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate.</measure>
    <time_frame>during chemotherapy assessed up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Extensive-stage Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Trilaciclib, carboplatin, etoposide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trilaciclib plus Carboplatin combined with Etoposide (first line ES-SCLC patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, carboplatin, etoposide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus Carboplatin combined with Etoposide (first line ES-SCLC patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trilaciclib, Topotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>plus Topotecan (second/third line ES-SCLC patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Topotecan</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus Topotecan (second/third line ES-SCLC patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trilaciclib</intervention_name>
    <description>Group 1: Trilaciclib, carboplatin, etoposide，or Topotecan Group 2: Trilaciclib, Topotecan Group 3: Placebo, carboplatin, etoposide，or Topotecan</description>
    <arm_group_label>Placebo, Topotecan</arm_group_label>
    <arm_group_label>Placebo, carboplatin, etoposide</arm_group_label>
    <arm_group_label>Trilaciclib, Topotecan</arm_group_label>
    <arm_group_label>Trilaciclib, carboplatin, etoposide</arm_group_label>
    <other_name>Carboplatin combined with Etoposide (first line ES-SCLC patients)</other_name>
    <other_name>plus Topotecan (second/third line ES-SCLC patients)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female of ≥ 18 years old;&#xD;
&#xD;
          2. Histology or cytology diagnosed extensive-stage small cell lung cancer ( ES-SCLC ) :&#xD;
&#xD;
          3. Patients who plan to receive carboplatin combined with etoposide: naïve with systemic&#xD;
             treatment (such as chemotherapy or combined immunotherapy) in the past&#xD;
&#xD;
          4. Patients planning to receive topotecan : previously received 1/2 line chemotherapy or&#xD;
             combined immunotherapy except for topotecan.&#xD;
&#xD;
          5. At least one measurable lesion without radiotherapy that meets RECIST1.1 standard;&#xD;
&#xD;
          6. Hemoglobin ≥ 90 g/L ;&#xD;
&#xD;
          7. Neutrophil count ≥ 1.5 × 109 /L ;&#xD;
&#xD;
          8. Platelet count ≥100 × 109 /L ;&#xD;
&#xD;
          9. Creatinine ≤ 15 mg /L or creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault&#xD;
             formula ) ;&#xD;
&#xD;
         10. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) ;&#xD;
&#xD;
         11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN or ≤ 5 ×&#xD;
             ULN (patients with liver metastases) ;&#xD;
&#xD;
         12. Albumin ≥ 30 g/L ;&#xD;
&#xD;
         13. ECOG PS score:0-2 ;&#xD;
&#xD;
         14. Expected survival time ≥ 3 months ;&#xD;
&#xD;
         15. Contraception :&#xD;
&#xD;
         16. Women: Women with potential fertility must have a negative serum pregnancy test result&#xD;
             at Screening, and take reliable contraceptive measures from signing informed consent&#xD;
             to 3 months after the last administration ;&#xD;
&#xD;
         17. Male: If a female partner has potential fertility, reliable contraceptive measures&#xD;
             must be taken after signing the informed consent to 3 months after the last&#xD;
             administration.&#xD;
&#xD;
         18. Understand and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptomatic brain metastases that require local radiotherapy or hormone therapy;&#xD;
&#xD;
          2. Other history of malignant cancer, except for: (1) clinically cured basal cell or&#xD;
             squamous cell tumors; (2) curable: a) cervical cancer, B) prostate cancer, C)&#xD;
             superficial bladder cancer; or ( 3 ) any solid tumor that it is clinically cured for 3&#xD;
             years or above;&#xD;
&#xD;
          3. Uncontrolled ischemic heart disease or congestive heart failure with clinically&#xD;
             significance (NYHA Class III or IV) ;&#xD;
&#xD;
          4. Stroke or cardiovascular and cerebrovascular events within 6 months before enrollment&#xD;
             ;&#xD;
&#xD;
          5. Severe active infection;&#xD;
&#xD;
          6. Potential inadequate compliance from psychological or other social factors;&#xD;
&#xD;
          7. Other uncontrolled severe chronic disease or condition, which considered by&#xD;
             Investigator as unsuitable for study participation;&#xD;
&#xD;
          8. Known HIV infection, active hepatitis B (defined as HBV DNA positive) and hepatitis C&#xD;
             (HCV RNA positive);&#xD;
&#xD;
          9. Received radiotherapy within 2 weeks before enrollment ;&#xD;
&#xD;
         10. Received cytotoxic or investigational drug treatment within 4 weeks, or non-cytotoxic&#xD;
             anti-tumor treatment within 2 weeks before enrollment;&#xD;
&#xD;
         11. For Part 1 patients, concomitant administration of strong or moderate inducer of&#xD;
             CYP3A4 within 4 weeks before study drug, or strong inhibitor of CYP3A4 within 2 weeks&#xD;
             before study drug;&#xD;
&#xD;
         12. Recovery from previous toxicity of anti-tumor treatments to Level 0 or 1 (except for&#xD;
             hair loss);&#xD;
&#xD;
         13. Allergy to the study drugs or any of their components (Trilaciclib, etoposide,&#xD;
             carboplatin, topotecan);&#xD;
&#xD;
         14. Unable to act independently by legal restrictions or in the legal sense;&#xD;
&#xD;
         15. Women who are pregnant or breastfeeding ;&#xD;
&#xD;
         16. Other patients who are considered unsuitable to participate in the study. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meina Yan, Doctor</last_name>
    <phone>+8618510219076</phone>
    <email>yanmeina@simcere.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jilin Cancer Hopspital</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ying Cheng</last_name>
      <phone>+860431-80596118</phone>
      <email>1165095416@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 8, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

